Semaglutide vs Placebo: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.0421 | 0.0381 | 0.0465 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.0523 | 0.0478 | 0.0571 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.0101 | -0.0164 | -0.00386 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.806 | 0.706 | 0.922 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.798 | 0.694 | 0.918 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer death from any cause on Semaglutide than on Placebo | 98.8 | 60.9 | 259 | from the risk difference interval | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Semaglutide | Participants received semaglutide subcutaneously once weekly in a fixed-dose escalation manner, with dose increases every 4 weeks for up to week 16 (0.25 mg, 0.5 mg, 1.0 mg and 1.7 mg) followed by maintenance dose of 2.4 mg once weekly up to the end of treatment period. | 371 | 8,803 | EG000 | ClinicalTrials.gov |
| Group 2 | Placebo | Participants received placebo (matched to semaglutide) subcutaneously once weekly up to the end of treatment period. | 460 | 8,801 | EG001 | ClinicalTrials.gov |
Harm 2
| Field | Value | Source |
|---|---|---|
| What it counts | Total, all-cause mortality | ClinicalTrials.gov |
| Time frame | From randomisation (week 0) up to 240 weeks | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity | ClinicalTrials.gov |
| NCT number | NCT03574597 | ClinicalTrials.gov |
| Phases | PHASE3 | ClinicalTrials.gov |
| Conditions | Overweight, Obesity | ClinicalTrials.gov |
| Interventions | Semaglutide, Placebo (semaglutide) | ClinicalTrials.gov |
| Lead sponsor | Novo Nordisk A/S | ClinicalTrials.gov |
| Results first posted | 2024-08-30 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT03574597?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.